5 Best Stocks That Will Always Grow

2. Eli Lilly and Company (NYSE:LLY)

1-year Revenue Growth Rate: 19.56%

3-year Revenue Growth Rate: 11.62%

5-year Revenue Growth Rate: 9.69%

Number of Hedge Fund Holders: 102

Eli Lilly and Company (NYSE:LLY) is a major player in the insulin market. Eli Lilly and Company (NYSE:LLY) was held by 102 hedge funds in Q4 of 2023 with stakes worth $11.18 billion. Fisher Asset Management is the most significant shareholder of the company and has a position worth $2.6 billion as of Q4 of 2023.

Eli Lilly and Company’s (NYSE:LLY) revenue increased 9.69% in the past five years. On April 12, Leerink reiterated an Outperform rating on the stock with an $821 price target.

Baron Funds stated the following regarding Eli Lilly and Company (NYSE:LLY) in its first quarter 2024 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company that discovers, develops, manufactures, and sells medicines in the categories of diabetes, oncology, neuroscience, and immunology, among other areas. Stock performance was strong due to robust fourth quarter sales of Mounjaro/ Zepbound, better-than-anticipated initial guidance for fiscal year 2024, and ongoing enthusiasm surrounding the company’s obesity and diabetes franchises. We continue to think Lilly is well positioned to grow revenue and earnings at attractive rates through the end of the decade and beyond.”